Stock Analiz

Molecular Partners AG MOLN

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$2.94Market cap $110M
Open the interactive analysis →

Molecular Partners AG (MOLN) is a healthcare company listed in the US with a market value of about $110M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -25%.

About Molecular Partners

Molecular Partners is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $21M in 2019 to $5M in 2024, a decline of about 23.6% a year. It was profitable in 1 of the last 7 years in our data.

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-59.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-640.0%
ROIC (5-yr avg.)-24.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue$0$5M$8M$205M$11M$11M$21M
Net income-$78M-$60M-$74M$128M-$70M-$71M-$38M
Free cash flow-$66M-$66M-$71M$127M-$101M-$35M-$2M
EPS (diluted)$-2.07$-1.59$-1.97$3.40$-1.86$-1.90$-1.00
Net margin—-1087.4%-880.7%62.2%-653.9%-671.7%-178.0%
ROIC-57.2%-34.1%-34.6%49.6%-46.7%-54.4%-53.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Molecular Partners pay a dividend?

Not currently.

Is Molecular Partners a good stock to buy?

We do not give buy or sell advice. Molecular Partners scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.